Brief: Xspray Pharma Obtains Results From Bioequivalence Studies With Hynap-Dasa ANDA

Xspray Pharma publ AB

13/10/2021 07:12

Oct 13 (Reuters) - XSpray Pharma AB (publ)  XSPRAY.ST :
    * XSPRAY PHARMA HAS OBTAINED RESULTS FROM BIOEQUIVALENCE
STUDIES
WITH HYNAP-DASA ANDA AND DECIDES TO FOCUS ON ITS IMPROVED
DASATINIB PRODUCT, DASYNOC™
    * BIOEQUIVALENCE WITH REFERENCE PRODUCT SPRYCEL WAS ACHIEVED
IN
FED BUT NOT IN FASTING SUBJECTS DUE TO HIGH VARIABILITY OF
SPRYCEL
    * TO FOCUS ENTIRELY ON IMPROVED VERSION, DASYNOC, WHICH HAS
ACHIEVED BIOEQUIVALENCE WITH A 30 PERCENT LOWER DOSE THAN
SPRYCEL
    * TO END DEVELOPMENT OF GENERIC VERSION OF DASATINIB.
    * SHORTER TIME IN PATENT WINDOW DECREASES IMPORTANCE OF
GENERIC
VERSION IN OUR PRODUCT PORTFOLIO

Source text for Eikon:  ID:nMFNcfBLT7 
Further company coverage:  XSPRAY.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))